• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Cardioxyl Pharmaceuticals

edit

Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don’t exist, are ineffective or are inadequate.

Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company’s core nitroxyl platform has generated several pre-clinical and clinical candidates including the company’s lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age.

Recent Milestones

edit

• 
  Cardioxyl Pharmaceuticals received $28M in Series B funding. (11/13/12)
  Posted 11/14/12 at 7:38pm via cardioxyl.com
• 
  Cardioxyl Pharmaceuticals received $14.5M in Series A funding. (12/6/06)
  Posted 10/31/10 at 7:22pm via cardioxyl.com
• 
  Cardioxyl Pharmaceuticals added Christopher A. Kroeger as President and CEO.
  Posted 8/2/10 at 5:42pm
• 
  Cardioxyl Pharmaceuticals added John Reardon as Chief Scientific Officer.
  Posted 3/13/13 at 5:04am

Videos

Screenshots

edit

Above: Cardioxyl Pharmaceuticals
Uploaded: 3/13/13

Sources

1. Cardioxyl Raises 14.5MM Series A Financing (cardioxyl.com) [edit]
2. Cardioxyl Pharmaceuticals Raises $28 Million in Series B Financing Led by OrbiMed Advisors (cardioxyl.com) [edit]